Maximizing the pricing and market access potential of new metabolism and endocrinology therapies
New mechanisms of action are an unmet need in the field of metabolic disease and endocrinology. However, the dominance of generic drugs in some indications creates price pressure for new entrants. A key consideration for manufacturers is therefore how to stratify large populations by risk, to target the new therapies where they can provide the greatest benefit.
In underserved indications, such as rare metabolic disorders, you need to develop innovative approaches to evidence generation and pricing. A tailored market access strategy is required for novel therapies.
Developing tailored pricing and market access strategies for metabolism and endocrinology therapies
Our strategic market access insight, pricing, and reimbursement expertise encompasses a range of indications, including:
- diabetes
- genetic disorders
- hypercholesterolemia
- osteoporosis.
Your tailored project will be led by members of our senior team. They like to be intellectually challenged and will be actively involved in your project, ensuring that your brief is integral to the work being conducted. They will tell you the whole story, and provide you with pragmatic, insightful, and clearly presented solutions.
We look forward to working with you on your market access challenges.
Request a call
